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1. INTRODUCTION
The World Health Organization (WHO) estimates that 30% of the 
global population, mainly in low-income countries, is deprived 
of regular access to essential medicines. A WHO study on pricing 
approaches and their impacts on availability and affordability of 
cancer drugs revealed that cancer drugs prices have been manipu-
lated, causing limited access to those in need [1]. This is also partic-
ularly true for the Association of Southeast Asian Nations (ASEAN). 
About 58% of the total hypertensive population and 52% of the total 
diabetic population in Cambodia went untreated, possibly due to 
the difficulties in accessing or paying for treatment [2]. Purchasing-
power-parity-adjusted mean unit prices of the originator cancer 
drugs bortemozib (3.5 mg vial) costs US$ 3622.22 in Malaysia and 
US$ 4630.12 in Thailand, whereas sunitinib malate (12.5 mg cap-
sule) costs US$ 150.47 in Malaysia and US$ 89.2 in Thailand [3]. 
Therefore, access to medicines has become a global issue and the 
WHO has prioritised this agenda in the Sustainable Development 
Goals as one of the focuses in the pursuit of universal health cover-
age [4]. Affordability and availability of medicines are two of the key 
determinants of access, in both public and private sectors [5].
2.  AFFORDABILITY AND AVAILABILITY  
OF MEDICINES
Association of Southeast Asian Nations, a regional intergovern-
mental organisation established in 1967, has positioned itself as 
an important platform for economic, political, and sociocultural 
cooperation and integration. ASEAN comprises 10 member coun-
tries, namely, Thailand, Vietnam, Indonesia, Malaysia, Philippines, 
Singapore, Myanmar, Cambodia, Laos, and Brunei. ASEAN is com-
mitted to improving access to health services for its communities 
with the establishment of ASEAN Strategic Framework on Health 
Development (2010–2015), reaffirming member countries com-
mitments to the WHO 2030 Agenda for Sustainable Development.
The rapid advancement in medical technology has brought large 
benefits but also contributes to the increased health spend-
ing, which is out-of-reach of patients and governments alike. 
Between 2000 and 2010, ASEAN countries have seen an increas-
ing trend of average annual growth rate in pharmaceutical 
spending per capita. Most ASEAN countries reported an aver-
age annual growth rate of above 6% with the exception of Brunei 
and Cambodia, registering a minimal growth rate of below 6% 
[6]. New and innovative health technologies have made the 
prices of medicines unjustifiably high and beyond the reach of 
the majority of the population.
A 2009 medicine price survey in the Philippines indicated that the 
public sector procured originator brand medicines at 26.33 times 
higher than the international reference prices, while the gener-
ics were procured at 7.97 times higher. Furthermore, the survey 
found poor affordability of the lowest-price generics in the public 
sector, whereby the standard treatment for most conditions cost 
more than 75% of a days’ wages [7]. Similarly, a 2005 price survey 
in Vietnam showed public procurement price for originator brand 
medicines were 8.29 times the international reference prices and 
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1.82 times the international reference prices for the lowest-price 
generics. Medicines in Vietnam are generally unaffordable, ranging 
from 0.7 days’ wages to obtain generic amoxicillin for acute respira-
tory infection treatment to 15.9 days’ wages for generic ceftriaxone 
in the public sector [8].
In the Philippines, 15 key medicines used for the treatment of 
common health conditions was found to be available only in 53.3% 
of the public health facilities. If the list is expanded to include 
medicines used to treat the most common causes of morbidity as 
recommended by WHO, the availability of generic and originator 
brand medicines were lower, at 27.5% and 8% of the public health 
facilities, respectively. Stock out duration in Philippine’s public 
health pharmacies was reported at 24.9 days and 43.8 days in the 
central-district warehouses [7]. Malaysian patients have alleged the 
lack of availability of certain cancer medicines (i.e., sunitinib) in 
the national formulary, forcing them to make exorbitant out-of-
pocket payments that may lead to financial catastrophe [9].
3. CROSS-BORDER COLLABORATION
Cross-border collaboration efforts are not a new strategy to improve 
access to medicines. Previous experience of collaboration efforts 
between the public and private sector has achieved remarkable 
results, through international organisations such as the Global Fund 
to Fight AIDS, Tuberculosis and Malaria (GFATM), the United 
States President’s Emergency Plan for AIDS Relief, UNITAID, and 
Gavi, The Vaccine Alliance. In recent years, more governments 
have come to a realisation that they stand a better chance to obtain 
better pricing and procurement terms as a joint network when 
dealing with drug manufacturers. Many years ago, such regional 
cooperation seemed inconceivable due to the fragmented and 
diverse nature of the healthcare system in individual countries. 
However, recent developments such as the creation of Belgium, the 
Netherlands, Luxembourg and Austria (BeNeLuxA) in 2015 (with 
Austria joining in June 2017), an intergovernmental regional col-
laboration between BeNeLuxA, have led to joint negotiations and 
information sharing. Following in the footsteps of BeNeLuxA, the 
Southern Mediterranean EU countries of Italy, Spain, Portugal, 
Malta, Cyprus, and Greece signed the Valletta Declaration in May 
2017 to jointly negotiate with the pharmaceutical industry on drug 
pricing and exchange of information. A regional network of Central 
European countries, namely the Czech Republic, Hungary, Poland, 
and Slovakia formed the Visegrád Group to jointly purchase med-
icines for rare diseases.
In 1979, ASEAN member countries adopted a broad framework 
known as the ASEAN Pharmaceuticals Project. Over the years, this 
collaboration has resulted in the development of several important 
milestones and integration of guidelines on pharmaceutical manu-
facturing and quality assurance, as shown in Figure 1.
In 1999, with the formation of Pharmaceutical Product Working 
Group (PPWG), harmonization of pharmaceutical regulations in 
ASEAN gained more traction. ASEAN Consultative Committee 
for Standards and Quality (ACCSQ)–PPWG is the main cor-
responding body in achieving accessibility of quality, safe, and 
efficacious products in the ASEAN region. The PPWG, over the 
years, has achieved various milestones, for instance [10,11]: (1) 
December 2005: feasibility study of an ASEAN Mutual Recognition 
Arrangement for pharmaceutical/medicinal products was com-
pleted; (2) December 2005: feasibility study of implementing a 
twinning system, where one member country could bridge the 
regulatory capacity and resource development voluntarily with 
another member country; (3) December 2005: postmarketing 
alert system was formalised for defective and unsafe pharmaceu-
tical/medicinal products; (4) March 2006: labelling standards for 
pharmaceutical/medicinal products were harmonised; (5) January 
2007: feasibility study of adopting a harmonised placement system 
for pharmaceutical/medicinal products into the ASEAN markets 
was initiated; and (6) December 2008: ASEAN Common Technical 
Dossier was implemented.
Nevertheless, the harmonisation efforts are seen as effective tools 
to facilitate the pharmaceutical trade in the region but offer less 
consideration to improve access to medicine. Leveraging on the 
success of harmonisation, regional cooperation and collaboration 
can provide practical solutions to make medicine more accessible. 
For example, the success of Pharmaceutical Inspection Cooperation 
Scheme among the signatories has paved the way for harmonisa-
tion of product registration and labelling.
In addition, high population mobility from ASEAN across the 
countries was reported; for example, the share of total migrants to 
Singapore and Malaysian population is 29.3% and 9.45%, respec-
tively [12]. Unofficial findings, taking into account the undocu-
mented migrants, show that the percentage of foreign workers is 
Figure 1 | Milestones of Association of Southeast Asian Nations Consultative Committee for Standards and Quality (ACCSQ) and Pharmaceutical 
Product Working Group (PPWG).
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estimated to be 20% of the Malaysian population [13]. Therefore, 
ASEAN large population and geographically close proximity of 
member countries, and expanding global opportunities in phar-
maceutical trade provide good leverage to implement cross- border 
collaboration, improving access to medicines and ultimately to 
contain pharmaceutical expenditure.
Strategic areas for collaboration may include the following.
3.1.  Establishing a Regional versus  
Centralised Pooled Procurement System
Globally, medicines are priced differently in each country based on 
the countries capacity and negotiating power. Purchasing countries 
with a small population or rare conditions with limited targeted 
populations have low bargaining power and are subjected to higher 
reference pricing [14]. The establishment of regional procure-
ment systems enables ASEAN member countries to achieve joint 
negotiation and pooled procurement, and creates an economy of 
scale, resulting in significant cost savings and efficiency. The Gulf 
Cooperation Council (GCC) model that consists of Bahrain, Kuwait, 
Oman, Qatar, Saudi Arabia, and the United Arab Emirates serves as 
a good role model for ASEAN. GCC coined the idea of establishing 
a group purchasing programme for pharmaceuticals and medical 
 supplies in 1976 [15]. The GCC started with 32 items worth US$ 
1 million, and the group purchasing programme currently contains 
>7000 items valued in excess of US$ 600 million. Since its inception, 
the programme has achieved >30% cost savings [16].
The bulk ordering and negotiation made collectively under the 
ASEAN umbrella for a population of >622 million could be advan-
tageous. However, one needs to take a cue from other multinational 
organisations such as the United States Agency for International 
Development and GFATM. For example, although it was opposed 
initially due to lack of autonomy by the health authorities of the 
member countries, the logistic application and implementation for 
GFATM in Benin, Ethiopia, and Malawi was managed using a cen-
tralised approach. Impartiality in decision-making was also crucial 
because their health decision-making was decentralised to provide 
personalised planning of HIV/AIDS activities.
To overcome the challenges of product fraud and supply chain issues, 
a harmonised effort towards joint regional rather than centralised 
pooled procurement will ensure that each country manages its own 
inventory and supply chain, thus bringing the shared benefit of better 
pricing mechanisms. In this way, an independent vertical system for 
each member country is applied to facilitate the control of commod-
ity security and distribution coordination at the country level.
This is because an integrated approach to ensure the commodity secu-
rity across >4.5 million km2 of land within the ASEAN region could 
entail an enormous amount of programme coordination. This is 
further complicated by the customs and bureaucratic issues because 
medicinal products are not exempted from cross-border movement.
3.2.  Establishing Mechanism for  
Information Sharing
Information asymmetry in medicine procurement and pricing has 
hindered the ability of governments to make efficient decisions 
and improves access to medicines. Governments are engaged with 
pharmaceutical companies in numerous types of managed-entry 
agreements and confidential rebates that hamper the use of ref-
erence pricing mechanisms. Such confidentiality actually under-
mines their negotiating power and does not guarantee lower prices 
[17]. Therefore, mechanisms to collect and exchange information 
are crucial to inform policymakers for decision-making processes. 
Information such as costs, pricing, and patent information should 
be collected and exchanged freely among ASEAN member coun-
tries. However, the current publicly available medicines price 
information among ASEAN countries is limited and compiled indi-
vidually by respective countries in their national languages, making 
price comparison a daunting task. It is noteworthy that in 2009, 
the WHO Regional Office for the Western Pacific initiated the 
Price Information Exchange for Essential Medicines (PIEMEDS) 
(www.piemeds.com); an information sharing platform that con-
tains medicine prices procured by the public sector. However, due 
to the voluntary reporting nature of the system that leads to poor 
response from member countries, potential benefits of PIEMEDS 
have not been optimised. Data in PIEMEDS were found to be 
outdated with limited coverage of medicine types, merely com-
prising the WHO EMEDS List. In addition, PIEMEDS does not 
capture data from all ASEAN member countries due to the fact that 
Indonesia, Myanmar, and Thailand are not part of WHO Western 
Pacific Region. Nevertheless, the entity of ASEAN is in a unique 
position to absorb and use the lessons and recommendations from 
PIEMEDS because of its complementary nature.
3.3.  Establishing Regional Joint  
Horizon Scanning
Horizon scanning is the systematic identification of new and emerg-
ing health technologies that have a potential impact on health and 
budgetary impact on health systems [18]. Horizon scanning is seen 
as the starting point of medicines accessibility [19]. In most ASEAN 
countries, horizon scanning is still in its infancy [20]. A quick 
check on Malaysian Ministry of Health website (www.moh.gov.my) 
showed only 11 horizon scanning reports produced to date. The 
establishment of joint horizon scanning will avoid duplication of 
efforts and reduce the resources needed from government [21]. Two 
possible areas of horizon scanning for ASEAN member countries 
to jointly carry out are the identification and filtration processes. 
Identification involves screening of new medicines that potentially 
enter the ASEAN market within the defined time horizon, while 
filtration selects products that are relevant to the country- specific 
needs, prior to the gathering of more in-depth data.
4.  MEASURES TO FACILITATE 
CROSS-BORDER COLLABORATION  
IN ASEAN
The development of cross-border collaboration is complicated 
and a difficult journey, involving various players from a diverse 
background with varied goals and objectives. Collaboration has 
to be worthwhile and achieves significant cost savings, efficiency, 
and other benefits, or otherwise, it will not materialise. Therefore, 
an understanding of how to work within the ASEAN structure is 
important for a successful cross-border collaboration. Approaches that 
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can be taken to prepare a conductive platform for cross-border col-
laboration are as follows:
 (1) Comprehensive understanding of healthcare system in each 
ASEAN member country. Countries with similar healthcare 
systems and contextual factors (population size and profile, geo-
graphical position, and disease burden) tend to achieve better 
collaboration. Multilateral discussion and framework agree-
ments at international level can overcome such differences. 
 (2) Establishing a roadmap for cross-border collaboration to 
guide member countries on clear, concrete steps to engage 
policy stakeholders in their respective countries. The roadmap 
should have common elements that are relevant to all member 
countries, yet individual countries can have their own national 
plan in implementing cross-border collaboration.
 (3) Formulating a legal framework for cross-border collaboration. 
Perhaps, the single most important barrier to a successful col-
laboration is the legal uncertainties. ASEAN member coun-
tries have different political and legal structures, thus it is vital 
to find a common path to institutionalise these differences 
before a functional framework agreements can be adopted.
 (4) Harmonising the procurement system, information collection, 
and reporting methodology. Harmonisation of procurement 
systems and procedures, along with the criteria for prequalifi-
cation of manufacturers, suppliers, and medicines are necessary. 
Furthermore, for any information to be beneficial, standardisa-
tion of methodology such as costing, measurement, selection of 
medicines, time horizons (for horizon scanning), and reporting 
techniques will bring better chance of successful collaboration.
 (5) Strengthening of political will. The presence of political will is 
necessary to begin the process of change. The ASEAN network 
and commitments can be the international drivers of change, 
highlighting the challenges in medicines access. Leaders of 
member countries need to champion the issues and give the 
continuous commitment, thus translating these commitments 
into sustainable actions. 
The PPWG may also undertake a nonvoluntary acquisition of the 
pharmaceutical patents pursuant to individual federal statutory 
authority, which could lower procurement costs by >90% [22]. 
Another aspect that the pharmaceutical regulatory agencies should 
consider is an online logistics management information network 
system connecting all member countries. This network system would 
be useful to track the payment and distribution of pharmaceutical 
products including the cold chain, controlled narcotics, etc. [23].
5. CONCLUSION
Cross-border collaboration is often put forward as a crucial strat-
egy for improving health outcomes; therefore, it should be tabled 
for discussion at the next ASEAN summit. The ASEAN trades and 
health ministers could emulate the development of ASEAN Sectoral 
Mutual Recognition Arrangement on Good Manufacturing Practice 
Inspection, which facilitates the ASEAN cross-border movement 
of pharmaceutical products by mutual exchange and recognition 
of Good Manufacturing Practice certifications. Furthermore, the 
presenting ministers of the ASEAN Sectoral Integration Protocol 
for Healthcare, as advised by PPWG, should further ratify the 
agreement to ensure ASEAN communities have access to medi-
cines, by making needed medicines available and affordable.
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